Literature DB >> 8856046

Gangliosides block antigen presentation by human monocytes.

A Heitger1, S Ladisch.   

Abstract

Gangliosides, immunosuppressive molecules shed by tumor cells, are potent inhibitors of monocyte accessory cell function. However, the specific monocyte cellular defect caused by gangliosides is unknown. Here we sought to delineate whether this abnormality is in the induction of suppressor cells, in intracellular antigen processing, or in intercellular antigen presentation. Three sets of studies of the tetanus toxoid (TT)-induced lymphoproliferative response, which is dependent upon monocyte accessory function, address this issue: (1) Antigen (TT)-primed human monocytes incubated with 50-100 microM human brain gangliosides for 24-48 h, washed, and then combined with T-cells, were inhibited in triggering T-cell proliferation, showing that the effect was occurring after antigen processing was complete. (2) T-cell responses to immobilized anti-CD3 or to antigen-primed control monocytes in the presence of ganglioside-exposed monocytes were unaffected, showing that ganglioside-exposed monocytes did not act as suppressor cells. (3) Stimulation by TT peptide fragment 830-843, which does not require processing, was completely inhibited by exposure of monocytes to gangliosides. These findings identify ganglioside interference with monocyte accessory cell function at the level of antigen presentation. We conclude that tumor gangliosides may inhibit host anti-tumor cellular immune responses by preventing the effective cellular interactions of the antigen-primed monocyte with the responding T-lymphocyte.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8856046     DOI: 10.1016/0005-2760(96)00091-4

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  16 in total

1.  IFN-γ and tumor gangliosides: Implications for the tumor microenvironment.

Authors:  Barbara Dillinger; Sarah Ahmadi-Erber; Manuel Lau; Markus A Hoelzl; Friedrich Erhart; Birgit Juergens; Dietmar Fuchs; Andreas Heitger; Stephan Ladisch; Alexander M Dohnal
Journal:  Cell Immunol       Date:  2018-02-02       Impact factor: 4.868

2.  Renal cell carcinoma-derived gangliosides suppress nuclear factor-kappaB activation in T cells.

Authors:  R G Uzzo; P Rayman; V Kolenko; P E Clark; M K Cathcart; T Bloom; A C Novick; R M Bukowski; T Hamilton; J H Finke
Journal:  J Clin Invest       Date:  1999-09       Impact factor: 14.808

3.  Ganglioside expression in tissues of mice lacking beta2-microglobulin.

Authors:  A Markotić; A Marusić; J Tomac; J Müthing
Journal:  Clin Exp Immunol       Date:  2002-04       Impact factor: 4.330

4.  Gangliosides inhibit the development from monocytes to dendritic cells.

Authors:  M Wölfl; W Y Batten; C Posovszky; H Bernhard; F Berthold
Journal:  Clin Exp Immunol       Date:  2002-12       Impact factor: 4.330

Review 5.  Sphingolipids and cell signalling.

Authors:  P Fredman
Journal:  J Inherit Metab Dis       Date:  1998-08       Impact factor: 4.982

6.  GD3, an overexpressed tumor-derived ganglioside, mediates the apoptosis of activated but not resting T cells.

Authors:  Gaurisankar Sa; Tanya Das; Christina Moon; Cynthia M Hilston; Patricia A Rayman; Brian I Rini; Charles S Tannenbaum; James H Finke
Journal:  Cancer Res       Date:  2009-03-10       Impact factor: 12.701

7.  Inhibition of glycolipid shedding rescues recognition of a CD1+ T cell lymphoma by natural killer T (NKT) cells.

Authors:  Venkataraman Sriram; Sungyoo Cho; Ping Li; Patrick W O'Donnell; Claire Dunn; Kyoko Hayakawa; Janice S Blum; Randy R Brutkiewicz
Journal:  Proc Natl Acad Sci U S A       Date:  2002-06-11       Impact factor: 11.205

8.  Mechanisms of ganglioside inhibition of APC function.

Authors:  Sheila Caldwell; Andreas Heitger; Weiping Shen; Yihui Liu; Barbara Taylor; Stephan Ladisch
Journal:  J Immunol       Date:  2003-08-15       Impact factor: 5.422

9.  GBM Derived Gangliosides Induce T Cell Apoptosis through Activation of the Caspase Cascade Involving Both the Extrinsic and the Intrinsic Pathway.

Authors:  Barun Mahata; Soumika Biswas; Patricia Rayman; Ali Chahlavi; Jennifer Ko; Ashish Bhattacharjee; Yu-Teh Li; Yuntao Li; Tanya Das; Gaurisankar Sa; Baisakhi Raychaudhuri; Michael A Vogelbaum; Charles Tannenbaum; James H Finke; Kaushik Biswas
Journal:  PLoS One       Date:  2015-07-30       Impact factor: 3.240

Review 10.  The dark side of dendritic cells: development and exploitation of tolerogenic activity that favor tumor outgrowth and immune escape.

Authors:  Barbara Seliger; Chiara Massa
Journal:  Front Immunol       Date:  2013-12-02       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.